Wyeth, Catalyst announce collaboration for hemophilia drug

COLLEGEVILLE, Pa. Two drug companies will collaborate to develop treatments for hemophilia and other bleeding conditions using a blood coagulant.

Wyeth and South San Francisco, Calif.-based Catalyst Biosciences announced Tuesday the formation of an exclusive worldwide collaboration to create treatments for hemophilia using Factor VIIa.

Under the terms of the agreement, Wyeth will pay Catalyst up to $40 million over the next two years, including a $21 million upfront payment. Additional research funding and milestone payments, not including royalties, could exceed $500 million.

Wyeth will support the discovery, research and clinical development by Catalyst of Factor VIIa, including the investigational drug CB 813, a hemophilia treatment. Wyeth will also be responsible for the development, manufacturing and global commercialization of products resulting from the collaboration and would have the right of first negotiation for additional clotting factors that Catalyst discovers.